Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study

Grigorios T. Gerotziafas, Despina Fotiou, BMBS, MA, Patrick Van Dreden, PhD, Theodoros N Sergentanis, Ismail Elalamy, MD PhD, Loula Papageorgiou, Matthieu Grusse, Stella Salta, Theodora Psaltopoulou, Annette Larsen, Evangelos Terpos, MD PhD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2018-99-114871

Published: 2018

Journal Articles

Defining the Balance between the Expression of Procoagulant, Anticoagulant and Angiogenic Molecules in Myeloma Plasma Cells

Loula Papageorgiou, Sandrine Thouronde, Patrick Van Dreden, PhD, Stella Salta, Laurent Garderet, MD PhD, Christelle Mazurier, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas, MD PhD

Blood (2017) 130 (Supplement 1): 5364.

https://doi.org/10.1182/blood.V130.Suppl_1.5364.5364

Published: 2017

Journal Articles

Procoagulant Phospholipid Dependent Clotting Time: A New Tool for the Identification of Multiple Myeloma Patients at Risk Poor Treatment Response

Fotiou Despina, Loula Papageorgiou, Stella Salta, Patrick Van Dreden, PhD, Evangelos Terpos, Jawed Fareed, PhD, Matthieu Grusse, Ismail Elalamy, MD PhD, Laurent Garderet, MD PhD, Christelle Mazurier, Grigorios T. Gerotziafas, MD PhD

Blood (2017) 130 (Supplement 1): 1110.

https://doi.org/10.1182/blood.V130.Suppl_1.1110.1110

Published: 2017

Journal Articles

An Ex Vivo Analysis of Thrombin Generation and Thromboelastometry in Patients Undergoing Treatment with Rivaroxaban Demonstrates Sustained Anticoagulant Effect and High Inter-Individual Variability

Stella Salta, Patrick Van Dreden, PhD, Loula Papageorgiou, Jawed Fareed, PhD, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas, MD PhD

Blood (2017) 130 (Supplement 1): 3722.

https://doi.org/10.1182/blood.V130.Suppl_1.3722.3722

Published: 2017

Journal Articles

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer Associated Thrombosis. the Observational Roadmap-CAT Study

Grigorios T. Gerotziafas, MD PhD, Patrick Van Dreden, PhD, Stella Salta, Loula Papageorgiou, Paraskevi Boura, Annette Larsen, Jawed Fareed, PhD, Konstantinos Syrigos, Ismail Elalamy, MD PhD

Blood (2017) 130 (Supplement 1): 2381.

https://doi.org/10.1182/blood.V130.Suppl_1.2381.2381

Published: 2017

NARROW

In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study

Defining the Balance between the Expression of Procoagulant, Anticoagulant and Angiogenic Molecules in Myeloma Plasma Cells

Procoagulant Phospholipid Dependent Clotting Time: A New Tool for the Identification of Multiple Myeloma Patients at Risk Poor Treatment Response

An Ex Vivo Analysis of Thrombin Generation and Thromboelastometry in Patients Undergoing Treatment with Rivaroxaban Demonstrates Sustained Anticoagulant Effect and High Inter-Individual Variability

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer Associated Thrombosis. the Observational Roadmap-CAT Study

Email alerts

ASH Publications

American Society of Hematology

In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study

Defining the Balance between the Expression of Procoagulant, Anticoagulant and Angiogenic Molecules in Myeloma Plasma Cells

Procoagulant Phospholipid Dependent Clotting Time: A New Tool for the Identification of Multiple Myeloma Patients at Risk Poor Treatment Response

An Ex Vivo Analysis of Thrombin Generation and Thromboelastometry in Patients Undergoing Treatment with Rivaroxaban Demonstrates Sustained Anticoagulant Effect and High Inter-Individual Variability

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer Associated Thrombosis. the Observational Roadmap-CAT Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only